TILS.L Regulatory News (TILS)

4 Mar 2005 07:00

ReGen Therapeutics PLC04 March 2005 ReGen Therapeutics Plc 4th March 2005 ReGen Therapeutics announces grant of U.S. patent on use of Colostrinin inDementia ReGen Therapeutics Plc ("ReGen" or the "Company"), a company whose productColostrinin has shown efficacy as a potential treatment for Alzheimer's disease,announces that a patent on the use of Colostrinin as a treatment for dementia,including Alzheimer's disease, has been granted by the United States Patent andTrademark Office. The grant of this patent adds further strength to the intellectual propertyportfolio owned by or licensed to ReGen. ReGen presently holds rights to elevenother patents issued since 2000 relating to the use of Colostrinin. The Companyhas filed a number of other patent applications in relation to Colostrinin itsconstituent peptides and analogues and these are currently being evaluated bythe relevant patent authorities. Commenting on the latest patent grant in the US, Chairman Percy Lomax said " Wenow have a patent covering the use of Colostrinin as a treatment for dementia,including Alzheimer's disease, in the largest Pharmaceutical and most developedNutraceutical market in the world. This is a very significant step commerciallyand adds strength to our negotiations with business partners." For further information, please contact: Andrew MarshallMarshall Robinson roeTel No 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange